What You Should Know:
– Komodo Health, recognized as the Evidentiary Standard for real-world data and healthcare analytics, and Nasdaq Data today announced a significant partnership.
– The collaboration will provide hedge funds, private equity firms, and venture capital firms with an unprecedented, in-depth view into the U.S. pharmaceutical and broader healthcare industries through a new dataset, the Nasdaq Medical Claims Insights (NMCI).
Nasdaq Medical Claims Insights (NMCI)
The newly launched Nasdaq Medical Claims Insights (NMCI) is an exclusive Nasdaq dataset sourced directly from Komodo Health’s Healthcare Map. This map stands as the most comprehensive source of de-identified, real-world data, tracking over 330 million longitudinal and real-time patient journeys across healthcare professionals (HCPs), healthcare organizations (HCOs), and various sites of care throughout the U.S.
NMCI provides extensive, de-identified information on these patient journeys, encompassing details on prescriptions (Rx), specialty pharmaceuticals, clinical records, electronic health and medical records (EHR/EMR), payer information, laboratory data, and more. Importantly, the dataset does not include any personally identifiable information, ensuring privacy.
Empowering Investment Decisions in the Healthcare Sector
The NMCI dataset is designed to empower market participants by enabling them to:
- Track key trends within the pharmaceutical and U.S. healthcare industries.
- Help forecast drug-specific and company-level revenues.
- Analyze shifts in market shares among industry players.
- Identify emerging drugs and promising companies.
“Komodo’s breadth, quality, and coverage of its insights combined with our data capabilities and innovation has unlocked a unique dataset that provides an in-depth view into the pharmaceutical and U.S. healthcare industries,” said Brandon Tepper, Senior Vice President and Global Head of Data at Nasdaq. “The Nasdaq Medical Claims Insights will empower market participants to access new opportunities and drive more informed investment decisions and strategies.”
